12月11日,中国国家药品监督管理局药品审评中心(CDE)官网最新公示,新开源参股公司永泰生物-B(06978.HK)研发的抗CD19单链抗体嵌合抗原受体T细胞注射液(简称CAR-T-19细胞注射液)成功被CDE纳入突破性治疗品种名单,适应症为25岁(含)以下复发/难治B细胞急性淋巴细胞白血病。 (文章来源:每日经济新闻)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.